- Conditions
- Advanced Lung Cancer, Dyspnea
- Interventions
- Dyspnea Intervention, Enhanced Usual Care
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Coral Gables, Florida • Boston, Massachusetts
Location Directory
Clinical trials in Boston, Massachusetts
This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
21516
Shown on this page
12
Current sort
Recently updated
Location scope
Boston, MA
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 601–612 of 21,516 matching trials in Boston, MA.
Live ClinicalTrials.gov results.
Institutions in Boston
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
- Interventions
- Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine, mFOLFOX6, zanidatamab, Docetaxel
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 26
- States / cities
- Cerritos, California • Los Angeles, California • Orange, California + 18 more
- Conditions
- Multiple Myeloma
- Interventions
- Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib, Pomalidomide, Isatuximab, Fianlimab, Cemiplimab, Nirogacestat, Cevostamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 13
- States / cities
- La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more
- Conditions
- C3G
- Interventions
- Placebo, iptacopan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Botensilimab, Balstilimab, Standard of Care
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Neurotrophic Keratopathy
- Interventions
- RGN-259, Placebo
- Drug
- Lead sponsor
- ReGenTree, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 41
- States / cities
- Vestavia Hills, Alabama • Laguna Hills, California • Loma Linda, California + 36 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
- Interventions
- VOY-101
- Biological
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Poway, California • Sacramento, California + 9 more
- Conditions
- T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
- Interventions
- CTX131
- Biological
- Lead sponsor
- CRISPR Therapeutics
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Stanford, California • Boston, Massachusetts + 3 more
- Conditions
- Lymphoma
- Interventions
- Rituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel, Fludarabine, Cyclophosphamide, Calcium folinate
- Drug · Biological
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Tampa, Florida • Chicago, Illinois + 11 more
- Conditions
- Parkinson Disease
- Interventions
- AAV2-GDNF gene therapy, control surgery
- Drug · Procedure
- Lead sponsor
- AskBio Inc
- Industry
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 26 more
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
- Interventions
- AP01, Placebo
- Drug · Other
- Lead sponsor
- Avalyn Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
- Conditions
- HPV Infection
- Interventions
- Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose
- Drug
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 352 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts